Lyell Immunopharma, Inc. (LYEL): Total Assets

Annual figures by period end, from SEC filings.

$340.05M
As of 2025-12-31
$311.15M
As of 2026-06-30
-28.7%
3-year compound annual growth
-17.8%
5-year compound annual growth
$1.13B2020-12-31: $908.28M2021-12-31: $1.13B2022-12-31: $937.56M2023-12-31: $750.03M2024-12-31: $490.86M2025-12-31: $340.05M$340.05M
2020-12-31 Total Assets (USD) 2025-12-31
Period endedTotal AssetsChange YoYSource filing
2025-12-31$340.05M-30.7%2026-03-12, Balance as of period end
2024-12-31$490.86M-34.6%2026-03-12, Balance as of period end
2023-12-31$750.03M-20.0%2025-03-11, Balance as of period end
2022-12-31$937.56M-16.8%2024-02-28, Balance as of period end
2021-12-31$1.13B+24.1%2023-02-28, Balance as of period end
2020-12-31$908.28Mn/a2022-03-29, Balance as of period end

Total Assets at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal AssetsChange YoY
Lyell Immunopharma, Inc. (LYEL)2025-12-31$340.05M-30.7%
Neonc Technologies Holdings, Inc. (NTHI)2025-12-31$2.82M-17.4%
Impact Biomedical Inc. (IBO)2025-12-31$17.41M-14.2%
Altimmune, Inc. (ALT)2025-12-31$279.93M+100.9%
Talphera, Inc. (TLPH)2025-12-31$29.72M+63.0%
HCW Biologics Inc. (HCWB)2025-12-31$24.52M-18.9%
Avalo Therapeutics, Inc. (AVTX)2025-12-31$116.46M-22.7%
Jupiter Neurosciences, Inc. (JUNS)2025-12-31$5.56M-10.3%
Connect Biopharma Holdings Ltd (CNTB)2025-12-31$56.08M-44.6%

Compare LYEL, NTHI, IBO, ALT side by side · Screen every company in Pharmaceutical Preparations ↗